MedTrace Logo

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

NCT06666439 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-20

No results posted yet for this study

Summary

The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

Conditions

  • Metastatic Invasive Lobular Carcinoma (mILC)

Interventions

DIAGNOSTIC_TEST

circulating tumor DNA (ctDNA)

Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.

Sponsors & Collaborators

  • Julia Foldi

    lead OTHER

Principal Investigators

  • Julia Foldi, MD, PhD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2029-10-31
Completion
2029-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06666439 on ClinicalTrials.gov